DA
BIIB icon

DCF Advisers’s Biogen BIIB Stock Holding History

DCF Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,500
Closed -$440K – 89
2025
Q4 		$440K Buy
+2,500
New +$408K 0.12% 82

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCF Advisers's BIIB Position: Q3 2024 in Review

DCF Advisers sold out of Biogen (BIIB) in Q3 2024, closing a stake of 1,000 shares — an estimated $232K sold.

DCF Advisers first reported a position in BIIB in Q2 2021 and held it in 4 quarters. The position peaked at $1.36M in Q1 2023. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • DCF Advisers reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • DCF Advisers sold 1,000 Biogen shares in Q3 2024, an estimated $232K.
  • DCF Advisers first reported a position in Biogen in Q2 2021 and held it in 4 quarters.
  • DCF Advisers's Biogen position peaked at $1.36M in Q1 2023.
  • 917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on DCF Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.